Management of obesity
This presentation is the property of its rightful owner.
Sponsored Links
1 / 15

Management of obesity PowerPoint PPT Presentation


  • 74 Views
  • Uploaded on
  • Presentation posted in: General

Management of obesity. continue. Specialist management Indications :extreme or life threatening obesity, presence of complications and associated risk factors of obesity, failure of general management 1) Drugs:

Download Presentation

Management of obesity

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Management of obesity

Management of obesity

continue


Management of obesity

Specialist management

Indications :extreme or life threatening obesity, presence of

complications and associated risk factors of obesity, failure of general

management

1) Drugs:

The classic sympathomimetic adrenergic agents (benz phetamine, mazindol, and phentermine) function by stimulating norepinephrine release or by blocking its reuptake in the ventromedial and lateral hypothalamic regions, drugs related to amphetamine have addictive potential

the fenfluramine/phentermine combination caused valvular heart disease.

These drugs have serious side effect that restricts their use in medical

practice


Management of obesity

Sibutramine :reduces food intake through B1 adrenoceptor and 5-HT receptor agonist activity,it increases metabolic rate via stimulation of peripheral B3 adrenocptor activity.

  • Adverse effects :dry mouth ,constipation, insomnia,tachycardia and hypertension

  • Contraindications to sibutramine use include uncontrolled hypertension, congestive heart failure, symptomatic coronary heart disease, arrhythmias, or history of stroke.

  • Monthly monitoring for the first 3 months is needed to ensure a good response and to detect adverse effects.

  • All patients should be monitored closely for blood pressure and pulse rate .A minority of patients will have hypertension and tachycardia that contraindicate the use of the medication.

  • Failure to lose weight during the first 1 to 2 months is a strong indicator of drug treatment failure and should also prompt the physician to discontinue sibutramine


Management of obesity

Orlistat :(Xenical) is a synthetic hydrogenated derivative of a naturally occurring lipase inhibitor

  • Orlistat is a potent, slowly reversible inhibitor of pancreatic, gastric, and carboxylester lipases and phospholipase A2, which are required for the hydrolysis of dietary fat into fatty acids and monoacylglycerols.

  • The drug acts in the lumen of the stomach and small intestine by forming a covalent bond with the active site of these lipases.

  • adverse effects: reported in at least 10% of orlistat-treated patients. These include flatus with discharge, fecal urgency, fatty/oily stool, and increased defecation. These side effects are generally experienced early, diminish as patients control their dietary fat intake.

  • bulk-forming laxatives (psyllium or methylcellulose) are helpful in controlling the orlistat-induced GI side effects when taken concomitantly with the medication.

  • Serum concentrations of the fat-soluble vitamins D and E may be reduced, and vitamin supplements are recommended to prevent potential deficiencies


Management of obesity

preconditions for drug therapy

Only used in patients of 18-75 years age

Only if the BMI >30 or >28 plus risk factors present

Other weight reduction advices already started

The patient should have lost at least 2.5 kg within the month prior to starting the drug

drug should be stopped after 3 months unless 5% of weight lost and stopped after 6 months unless 10% of weight lost.

The whole duration of treatment should not exceed 24 months

Treatment of associated depression is a problem since tricyclic antidepressant drugs increase weight gain ,5HT reuptake inhibitors (fluoxitine) avoids this side effect

Thyroid hormone replacement only used in the presence of biochemical evidences of hypothyroidism


Management of obesity

4))Very low calorie diets

Under the supervision of experienced physician and a nutritionist

Deaths had occured, some from documented ventricular tachycardia and fibrillation.

Indicated for individuals of BMI >30 to induce a weight loss of 1.5-2.5 kg per week

Should include a protein content of 50 gm and 40 gm for male and female respectively, energy contents of 500 kcal and 400 kcal for male and female respectively

Side effects :orthostatic hypotension ,headache , diarrhea and nausea


Surgical management

Surgical management

Indications: for those with BMI of >40 or >35 plus risk factors or

life threatening co morbid diseases.

Hypertension, hyperlipidemia and diabetic glycemic control are markedly

improved but short term post operative and long term medical complications

need careful follow-up of these patients

Vertical band gastroplasty and gastric bypass procedures involve creation of

a similar small pouch but with drainage into a loop of jejunum rather than into

the lower stomach.

Jaw wiring and use of liquid food,but weight regain after unwiring is usual

Apronectomy is used for removal of overhanging abdominal fat

Jejunoileal bypass has unacceptable mortality and morbidity thus , no longer

recommended


Management of obesity

Protein–energy malnutrition


Management of obesity

Protein–energy malnutrition

occurs as a result of a relative or absolute deficiency of energy and protein.

It may be primary, due to inadequate food intake,

or secondary, as a result of other illness.

  • For most developing nations.

    In children, starvation (protein-energy malnutrition, PEM) is manifest as the syndromes of kwashiorkor (malnutrition with oedema) and marasmus (malnutrition with marked muscle-wasting).

  • In industrialized societies, protein–energy malnutrition is most often secondary to other diseases.

    Kwashiorkor-like secondary protein–energy malnutrition occurs primarily in association with hypermetabolic acute illnesses such as trauma, burns, and sepsis.

    Marasmus-like secondary protein–energy malnutrition typically results from chronic diseases such as chronic obstructive pulmonary disease (COPD), congestive heart failure, cancer, or AIDS.


In adults

In adults

The predominant form of PEM is under nutrition results from a sustained negative energy balance.

Etiology

  • Insufficient food supply

  • Persistent regurgitation or vomiting

  • Anorexia

  • Malabsorption

  • Increased energy requirement e.g. thyrotoxicosis

  • Increased calorie loss e.g. glucosuria in diabetes mellitus

    Under nutrition often leads to vitamin deficiency esp. thiamin ,folate and vit C.

    Diarrhea is also seen in these patients leading to loss of sodium ,potassium and magnesium


Management of obesity

Pathophysiology

  • In the first 24 hours following low dietary intake, the body relies for energy on the breakdown of hepatic glycogen to glucose, then gluconeogenesis to maintain glucose levels.

  • The majority of protein breakdown takes place in muscle releasing amino acids (used for gluconeogenesis), with eventual loss of muscle bulk.

  • Lipolysis, The stored triglyceride is hydrolysed by lipase to glycerol (used for gluconeogenesis), and to non-esterified fatty acids that can be used directly as a fuel or oxidized in the liver to ketone bodies.


Clinical features

Clinical features

  • Loss of weight

  • Thirsty ,weakness, nocturia ,amenorrhea ,impotence and craving for food

  • Lax ,pale ,dry skin ,loss of turgor and occasionally pigmented patches

  • Hair thinning , cold and cyanosed extremities , pressure sore

  • Muscle wasting and Loss of subcutaneous fat

  • Odema even in the absence of hypo albuminemia

  • Slow pulse , low blood pressure and small heart

  • Distended abdomen with diarrhea

  • Diminished tendon jerk

  • Apathy , loss of initiatives , depression introversion

  • Susceptibility to infections


Management of obesity

  • The most common cause of death in famine is infections and the usual signs of infection may not appear

  • All organs atrophy except the brain

  • Old people are more vulnerable to death


Investigations

Investigations

In addition to calculation of BMI

  • Plasma free fatty acid increases ; Ketosis and acidosis

  • Plasma glucose decreases

  • Serum albumin is normal

  • Urine has fixed specific gravity, creatinine excretion is low

  • Mild anemia, thrombocytopenia and leukopenia ,

    Anaemia due to folate and iron deficiency.

    Eosinophilia suggests parasitic infestation.

  • ESR is normal unless there is infections

  • Delayed skin sensitivity tests e.g tuberculin test is false negative

  • ECG shows sinus bradycardia and small voltage

  • Stools should be examined for parasitic infestations.

  • Chest X-ray - tuberculosis is common and is easily missed if a chest X-ray is not performed.


  • Login